Compare SPH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPH | CRVS |
|---|---|---|
| Founded | 1945 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1996 | 2016 |
| Metric | SPH | CRVS |
|---|---|---|
| Price | $20.21 | $13.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.20 |
| AVG Volume (30 Days) | 88.8K | ★ 1.1M |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | ★ 6.38% | N/A |
| EPS Growth | 42.11 | ★ 48.04 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,432,518,000.00 | N/A |
| Revenue This Year | $2.06 | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $29.54 | ★ N/A |
| Revenue Growth | ★ 7.94 | N/A |
| 52 Week Low | $17.30 | $2.54 |
| 52 Week High | $21.72 | $26.95 |
| Indicator | SPH | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 37.00 |
| Support Level | $20.00 | $12.95 |
| Resistance Level | $20.70 | $18.73 |
| Average True Range (ATR) | 0.40 | 0.99 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 14.67 | 10.92 |
Suburban Propane Partners LP distributes propane, renewable propane, renewable natural gas (RNG), fuel oil, refined fuels, and markets natural gas and electricity in deregulated markets. It produces and invests in low-carbon fuel alternatives. The company installs and services home comfort heating and ventilation equipment and distributes fuel oil, kerosene, diesel, and gasoline to about 25,000 residential and commercial customers mainly in the U.S. northeast. It operates three segments: Propane, Fuel Oil and Refined Fuels, and Natural Gas and Electricity, with the Propane segment generating the majority of revenue. Propane, a by-product of natural gas processing and petroleum refining, is a clean-burning energy source known for transportability and ease of use.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.